COSM - Cosmos Holdings Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.7000
0.0000 (0.00%)
As of 3:27PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.7000
Open2.7200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.7000 - 2.7000
52 Week Range2.0300 - 7.4900
Volume4
Avg. Volume1,260
Market Cap35.336M
Beta (3Y Monthly)2.42
PE Ratio (TTM)N/A
EPS (TTM)-1.0060
Earnings DateApr 23, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Cosmos Holdings Engages Exchange Listing To Assist with its NASDAQ-Listing

    Cosmos Holdings Inc. (COSM) (the “Company”) today announced it has engaged Exchange Listing LLC to assist with the planning and implementation of an up-listing of its common stock to the NASDAQ Capital Markets. “We plan to list our securities on NASDAQ Capital Markets as a next stage in our corporate growth and development,” said Greg Siokas, Chief Executive Officer of Cosmos Holdings. “Stock exchanges have complex rules and policies relating to new listings and the establishment and maintenance of an appropriate corporate governance structure,” said Peter Goldstein, Co-Founder and Chairman of Exchange Listing.

  • GlobeNewswire

    Cosmos Holdings, Inc. Completes $550,000 Debt-to-Equity Conversion at $7.50 Per Share

    CHICAGO, June 25, 2019 -- Cosmos Holdings, Inc. (“Cosmos” or the “Company”) (OTCQB: COSM), an international pharmaceutical company, announced today it agreed to issue 73,334.

  • GlobeNewswire

    Cosmos Holdings, Inc. Completes $500,000 Debt-to-Equity Conversion at $7.50 Per Share

    Cosmos Holdings, Inc. (“Cosmos” or the “Company”) (COSM), an international pharmaceutical company, announced today it agreed to issue 66,667 shares of common stock to Grigorios Siokas, the Company’s CEO, in exchange for the repayment of $500,000 of loans due to Mr. Siokas. The effective conversion rate is $7.50 per share, 117% higher than the $3.45 closing share price of Cosmos on May 29, 2019. Following the conversion of the loans, Cosmos will have a total of 13,154,145 shares of common stock outstanding.

  • GlobeNewswire

    Cosmos Holdings, Inc. Announces Year End 2018 Financial Results

    CHICAGO, April 23, 2019 -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced its full-year 2018 financial results for the.

  • GlobeNewswire

    Cosmos Holdings, Inc. Adds to Its Advisory Board

    Cosmos Holdings, Inc. ("the Company") (COSM), an international pharmaceutical company, announced that it has added executive Vassos Efthymiadis to its advisory board.  Mr. Efthymiadis is the Managing Director of K&N Efthymiadis S.A. and Vice President of the Redestos Agrotechnology Group, both companies are leaders in agribusiness in Greece.  Mr. Efthymiadis is also President of the Hellenic Crop Protection Association, Board Member of the Hellenic Association of Chemical Industries, and Advisory Board Member of the International Hellenic University.

  • GlobeNewswire

    Cosmos Holdings, Inc. Pays Off All Convertible Debt

    CHICAGO, Feb. 06, 2019 -- Cosmos Holdings, Inc. (OTCQB: COSM), an international pharmaceutical company, announced today that it paid off the remaining balance of its.

  • GlobeNewswire

    Cosmos Holdings, Inc. Adds Distinguished Portfolio Manager With Mid-Cap & Large-Cap Value Expertise to Its Advisory Board

    Cosmos Holdings, Inc. ("the Company") (COSM), an international pharmaceutical company, announced that it has added Tom Kolefas to its Advisory Board. “Tom Kolefas brings a wealth of expertise to our company,” said Grigorios Siokas, Chief Executive Officer of Cosmos Holdings.

  • GlobeNewswire

    Cosmos Holdings, Inc. Acquires Cosmofarm Ltd.

    CHICAGO, Dec. 21, 2018 -- Cosmos Holdings, Inc. (OTCQB: COSM), an international pharmaceutical company, announced the closing of its acquisition of Cosmofarm Ltd (“Cosmofarm”),.

  • GlobeNewswire

    Cosmos Holdings, Inc. Welcomes Dr. Ioannis Dedes MD to Its Advisory Board

    CHICAGO, Nov. 28, 2018 -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced that it has added to its advisory board - Dr..